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Background: There is variation in the use of radioactive iodine (RAI) as treatment for well-differentiated thyroid
cancer. The factors involved in physician decision-making for RAI remain unknown.
Methods: We surveyed physicians involved in postsurgical management of patients with thyroid cancer from
251 hospitals. Respondents were asked to rate the factors important in influencing whether a thyroid cancer
patient receives RAI. Multivariable analyses controlling for physician age, gender, specialty, case volume, and
whether they personally administer RAI, were performed to determine correlates of importance placed on
patients’ and physicians’ worry about death from cancer and differences between low– versus higher–case-
volume physicians.
Results: The survey response rate was 63% (534/853). Extent of disease, adequacy of surgical resection, patients’
willingness to receive RAI, and patients’ age were the factors physicians were most likely to report as quite or
very important in influencing recommendations for RAI to patients with thyroid cancer. Interestingly, both
physicians’ and patients’ worry about death from thyroid cancer were also important in determining RAI use.
Physicians with less thyroid cancer cases per year were more likely than higher-volume physicians to report
patients’ ( p < 0.001) and physicians’ worry about death ( p = 0.016) as quite or very important in decision-making.
Other factors more likely to be of greater importance in determining RAI use for physicians with lower thyroid
cancer patient volume versus higher include the accepted standard at the affiliated hospital ( p = 0.020), beliefs
about RAI expressed by colleagues comanaging patients ( p = 0.003), and patient distance from the nearest facility
administering RAI ( p = 0.012).
Conclusion: In addition to the extent of disease and adequacy of surgical resection, physicians place importance
on physician and patient worry about death from thyroid cancer when deciding whether to treat a patient with
RAI. The factors important to physician decision-making differ based on physician thyroid-cancer case-volume,
with worry about death being more influential for low–case-volume physicians. As the mortality from thyroid
cancer is low, the importance placed on death in decision making may be unwarranted.
Introduction
The incidence of well-differentiated thyroid cancer isrising, and the American Cancer Society estimates that
there will be 56,450 new cases in the year 2012 (1). Despite
the rise in thyroid cancer incidence, there has not been an
associated increase in mortality rates (2–5). Five-year survival
rates reach 97% for all thyroid cancers and 100% if contained
in the thyroid (6).
The use of radioactive iodine (RAI) for remnant ablation
following surgical resection for well-differentiated thyroid
cancer has increased (7,8), but there is still controversy re-
garding the effectiveness of postoperative RAI use for re-
ducing mortality and disease-specific survival in the majority
of thyroid cancer patients (9–12). Recently, a study found that
postoperative RAI used for well-differentiated thyroid can-
cers does not impact survival of patients designated as low
risk after thyroidectomy (13). The increasing use of RAI in
thyroid cancer has health implications, as the risk–benefit
ratio for RAI use may not be favorable in low-risk patients.
Reported adverse effects include eye/nasolacrimal, salivary,
pulmonary, gastrointestinal, hematopoietic, and gonadal
dysfunction, as well as development of second primary ma-
lignancies (8,14–16). Moreover, escalating healthcare costs
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from unnecessary RAI use in these patients will be unjusti-
fiable. Although our previous work has demonstrated a
relationship between surgeon preference for more intensive
management and greater subsequent RAI use (17), and be-
tween the specialty of the primary decision-maker and RAI
use (18), the factors that contribute to physician decision-
making for RAI use post-thyroid surgery remain unknown.
In an effort to identify the factors that influence whether a
physician recommends that a thyroid cancer patient receive
RAI after thyroid surgery, we surveyed nonsurgical physi-
cians involved in thyroid cancer management.
Methods
Data source and study population
As previously described by Haymart et al. (17,18), surgeons
from randomly sampled hospitals affiliated with the National
Cancer Database were surveyed. The 560 surgeon respon-
dents were then asked to ‘‘please list the names, specialties,
and hospital affiliations of the physicians who provide care
to your thyroid cancer patients or administer RAI when
needed.’’ The 903 physicians identified by the surgeons were
the subjects of this second survey study.
The modified Dillman survey method (19) was used to
enhance survey response rates. This protocol consists of (i)
an initial mailing of an introductory letter, the survey
instrument, a postage-paid return envelope, and a small gift,
(ii) a postcard reminder 3weeks later, and (iii) a second survey
with a postage-paid return envelope to all nonresponders
after another 2 weeks.
Data from the survey were de-identified and the double
entry method was used to ensure < 1% error. The study was
granted exemption by the University of Michigan Institu-
tional Review Board.
Measures
Before administration to targeted physicians, the survey
instrument was piloted in a multidisciplinary group of pro-
viders at the University of Michigan. The survey instrument
was created and reviewed by a multidisciplinary group of
providers, consisting of health services researchers involved
in survey methodology and providers from the fields of en-
docrinology, surgery, and nuclear medicine. The instrument
was then piloted in a cohort of endocrinologists and nuclear
medicine physicians in Ann Arbor, Michigan. After piloting,
minor revisions were made before survey administration.
Subsequently, the survey was administered. A 5-point
Likert scale was used for the 17 survey items addressing
factors involved in RAI decision making, with the following
options: 1=not at all important, 2 = a little important,
3 = somewhat important, 4 =quite important, and 5 =very
important. Respondents were asked to rate the following
factors’ importance in influencing whether a thyroid cancer
patient receives RAI: extent of disease, adequacy of surgical
resection, patient age, the accepted standard of care at the
affiliate hospital, the beliefs about RAI treatment expressed by
colleagues comanaging the patient, patient level of flexibility
at work, patient willingness to receive RAI, patient interest in
conceiving a child, presence of young children in the patient’s
home, patient distance from nearest facility that administers
RAI, patient ability to tolerate thyroid hormone withdrawal
before RAI, patient anxiety about their diagnosis and prog-
nosis, patient worry about complications from RAI, patient
worry about death from thyroid cancer, physician worry
about litigation, physician worry about complications from
RAI, and physician worry about patient death from thyroid
cancer.
Statistical analysis
The 5-point Likert scale used to rate the factors influencing
use of RAI for thyroid cancer was dichotomized to very and
quite important versus not at all, a little, and somewhat
important. Descriptive statistics were generated.
Based on the survey, the provider case-volume was
categorized in intervals of 0–4, 5–24, 25–49, 50–99, and 100
or more patients with thyroid cancer seen in 1 year. Multi-
variable logistic regression analysis controlling for gender,
age, specialization, provider case volume, and whether
providers personally administer RAI, was performed to de-
termine correlates of importance placed on patient’s and
physician’s worry about death. Additional multivariable
logistic regression analyses controlling for gender, age,
specialization, and whether providers administer RAI, were
performed evaluating differences between low versus higher
case volume physicians.
All statistical tests were performed using SAS 9.2 (SAS
Institute, Inc., Cary, NC). Two-sided tests were used with
p < 0.05 considered as statistically significant.
Results
Seventeen of 903 surveyed physicians were found to be
ineligible for the survey because theywere unreachable due to
incorrect mailing address and 33 were ineligible because they
were deceased, ill, retired, or not treating thyroid cancer pa-
tients. Of the 853 response-eligible physicians, 534 (63%)
completed the survey; these respondents represent 251 of the
sampled hospitals.
Table 1 shows the respondent characteristics. The majority
of the respondents were white and male (79% and 74%, re-
spectively), and the mean age was 52 years. Respondents had
an average of 20 years in practice; 67% were endocrinologists,
15% nuclear medicine providers, 10% other, 5% oncologists,
and 2% radiologists. From the category other, 71% answered
radiation oncology as their specialization. In regard to prac-
tice setting, 57% were in private practice, 23% in an academic
tertiary care center, 15% in a community-based academic
affiliate, and 5% in other settings. Of the respondents, 62%
answered that they do not routinely administer RAI in their
practice.
Figure 1 shows that the extent of disease (94%), adequacy of
surgical resection (87%), patients’ willingness to receive RAI
(64%), and patients’ age (62%) were reported to be important
factors influencing recommendations regarding RAI use for
patients with thyroid cancer. Both physicians’ (53%) and
patients’ (45%) worry about death from thyroid cancer were
also important in determining RAI use. Physicians with less
thyroid cancer cases per year were more likely to report
physicians’ and patients’ worry about death as quite or very
important in decision making. The median values for the 17
factors that influence RAI use are listed in Table 2.
In analyzing responses from providers surveyed by region,
we found that there was variability in the degree to which
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providers rated the importance of hospital standards in their
decision making regarding RAI use. The physicians surveyed
from the East South Central region placed the least impor-
tance, while the physicians surveyed from the Mid-Atlantic
region placed the most importance on hospital standards
( p-value < 0.001). None of the other sixteen survey items
differed by region.
After controlling for physician gender, age, specialization,
and whether the provider personally administers RAI, lower
volume physicians were statistically more likely to place im-
portance on patients’ worry ( p< 0.001) (Fig. 2A and Table 3)
and physicians’ worry about death ( p = 0.016) compared to
high-volume physicians (Fig. 2B and Table 4). Other factors
more likely to be rated as quite or very important to physi-
cians with lower thyroid cancer patient volume include ac-
cepted standards at affiliated hospital ( p = 0.020), beliefs
about RAI expressed by colleagues comanaging patients
( p = 0.003), and patient distance from the nearest facility
administering RAI ( p= 0.012).
Discussion
The results of this study improve our knowledge of the
factors that influence whether a physician recommends RAI
for a patient with well-differentiated thyroid cancer. Extent of
disease, adequacy of surgical resection, patients’ willingness
to receive RAI, and patients’ age were the most important
factors influencing recommendations regarding RAI use for
FIG. 1. Factors physicians report as quite or very important
in influencing whether a patient receives radioactive iodine
(RAI) therapy for treatment of thyroid cancer.
Table 1. Provider Characteristics
n (%)
Gender
Male 382 (74)
Female 135 (26)
Ethnicity
White 399 (79)
African-American 9 (2)
American Indian/Alaska Native 2 (0)
Asian 81 (16)
Hispanic 19 (4)
Other 17 (3)
Years in practice (mean– SD) 19.76– 10.85
Age (mean – SD) 51.75– 11.38
Specialization
Endocrinology 359 (67)
Nuclear medicine 81 (15)
Radiology 11 (2)
Oncology 27 (5)
General practitioner 2 (0)
Other 52 (10)
Practice setting
Private practice 300 (57)
Community-based academic affiliate 80 (15)
Academic tertiary care center 121 (23)
Other 25 (5)
Country region
East North Central 98 (18)
East South Central 40 (7)
Mid-Atlantic 74 (14)
Mountain 31 (6)
New England 37 (7)
Pacific 67 (13)
South Atlantic 105 (20)
West North Central 51 (10)
West South Central 28 (5)
Number of thyroid cancer patients physician sees in 1 year
0–4 18 (4)
5–24 143 (28)
25–49 137 (27)
50–99 112 (22)
100 or more 98 (19)
Physician administers RAI
Yes 195 (38)
No 316 (62)
RAI, radioactive iodine.
Table 2. Median Values for the 17 Factors
That Influence Radioactive Iodine Use
Median
value
Extent of surgery 5
Adequacy of surgical resection 5
Patient’s age 4
Accepted standard at the affiliated hospital 3
Beliefs about RAI treatment
expressed by colleagues comanaging the patient
3
Patient’s level of flexibility at work 2
Patient willingness to receive RAI 4
Patient interest in conceiving a child 3
Presence of young children in the patient’s home 3
Patient distance from nearest facility
that administers RAI
2
Patient ability to tolerate thyroid
hormone withdrawal before RAI administration
3
Patient anxiety about their diagnosis and prognosis 3
Patient worry about complications from RAI 3
Patient worry about death from thyroid cancer 3
Physician worry about litigation 2
Physician worry about complications from RAI 3
Physician worry about patient
death from thyroid cancer
4
The range for all 17 items was 1–5.
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patients with thyroid cancer. Interestingly, patients’ and
physicians’ worry about death also played an important role
in decision making. Compared to higher volume physicians,
physicians with less thyroid cancer cases each year were more
likely to prioritize patients’ worry and physicians’ worry
about death, accepted standards at affiliated hospital, beliefs
about RAI expressed by colleagues comanaging patients, and
patient distance from the nearest facility administering RAI.
Previous work has shown a significant rise in the propor-
tion of patients withwell-differentiated thyroid cancer treated
with RAI after surgery, as well as a wide hospital-level vari-
ation in RAI use in these patients (7). It is now known that
both the specialty of the primary decision maker (18) and the
thyroid surgeon’s tendency for more aggressive management
are associated with greater RAI use in patients with low-risk
disease (17). However, the clinical and nonclinical factors
influencing physician decision making in RAI use have not
been previously studied. As the most recent clinical guide-
lines leave the use of RAI to provider discretion in a large
proportion of patients (20), understanding the clinical and
nonclinical factors that providers use in their decision-making
process is critical to understanding the rise in RAI use. This
knowledge will ultimately encourage tailoring of treatment to
disease severity. Our study has shown that significant im-
portance is placed on both physicians’ and patients’ worry
about death. This is remarkable considering that there is un-
clear survival benefit to RAI use in the majority of thyroid
cancer patients as most patients have an excellent prognosis
regardless of intervention (10,20–22). A recent study by
Schvartz et al., with follow-up of 10.3 years, failed to prove
any survival benefit of RAI after surgery in a large cohort of
FIG. 2. (A) Percentage of physicians who felt patient
worry about death is quite or very important in influencing
whether the patient receives RAI therapy for thyroid cancer.
(B) Percentage of physicians who felt physician worry about
death is quite or very important in influencing whether the
patient receives RAI therapy for thyroid cancer.
Table 3. Multivariable Analysis of Physician
Characteristics Associated with Importance
Placed on Patient Worry About Death
in Determining Radioactive Iodine Use
Physicians reporting
patient worry about
death as quite or very
important for decision
on RAI use [n (%)]
Multivariable
p-value
Gender 0.634
Male 169 (43)
Female 60 (45)
Age 0.245
< 50 years old 132 (46)
> 50 years old 97 (41)
Specialization
Endocrinology 157 (44) Ref.
Nuclear medicine 30 (38) 0.136
Other 42 (47) 0.979
Number of thyroid cancer
patients seen in 1 year
< 0.001
0–4 12 (67)
5–24 67 (47)
25–49 69 (51)
50–99 42 (38)
100 or more 30 (31)
Administer RAI 0.067
Yes 99 (46)
No 130 (42)
Table 4. Multivariable Analysis of Physician
Characteristics Associated with Importance
Placed on Physician Worry About Death
in Determining Radioactive Iodine Use
Physicinas reporting
physician worry about
death as quite or very
important for decision
on RAI use [n (%)]
Multivariable
p-value
Gender 0.214
Male 197 (50)
Female 74 (56)
Age 0.124
< 50 years old 116 (49)
> 50 years old 155 (53)
Specialization
Endocrinology 185 (52) Ref.
Nuclear medicine 36 (45) 0.147
Other 50 (56) 0.479
Number of thyroid cancer
patients seen in 1 year
0.016
0–4 11 (61)
5–24 77 (54)
25–49 82 (61)
50–99 51 (46)
100 or more 40 (41)
Administer RAI 0.448
Yes 111 (52)
No 160 (51)
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low-risk, well-differentiated thyroid cancer patients (13).
Moreover, the benefits of RAI use in these patients may not
always exceed the risks (8,14,15).
Several studies have investigated the importance of worry
about death from cancer when considering treatment, espe-
cially among breast and ovarian cancer patients (23,24).
However, these primarily focus on patients with advanced
cancer. Our study’s results are novel, in that, worry about
death appears to influence treatment in a cancer with a gen-
erally favorable prognosis.
The strengths of this study include an innovative research
question, a large sample size of providers and hospitals, and a
high response rate among providers. However, this study has
limitations. First, survey studies in general carry a risk for
nonresponse bias. Second, it is not known whether the
provider report to the survey questions is consistent with
provider treatment behavior. Third, although the survey
included a comprehensive set of factors that may influence
physician decisionmaking, there may be other factors that we
did not inquire about. Finally, although this study focuses
solely on the physician, the patient is also involved in the
decision-making process.
Despite its limitations, this study sheds light onto some of
the factors involved in provider decision making in regard to
RAI use in patients with well-differentiated thyroid cancer.
Surprisingly, importance is placed on worry about death by
both patients and providers. As the mortality from well-
differentiated thyroid cancer is low, the importance placed on
death in decision making may be unwarranted. Fear may be
driving the rise in RAI use, suggesting a role for better pro-
vider education and further research into the risk–benefit of
low-risk thyroid cancer treatments.
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